MedWatch

Lundbeck's former head of North America appointed CEO of Capsida Biotherapeutics

Peter Anastasiou, who has spearheaded Danish pharmaceutical firm Lundbeck's operation in the US where he oversaw the launch of migraine drug Vyepti, has revealed the next step in his career on LinkedIn. In November, he announced his departure from Lundbeck.

Going forward, Lundbeck's former head of North America, Peter Anastasiou, will be in charge of US-based biotech firm Capsida Biotherapeutics | Photo: Lundbeck / PR

Lundbeck's departing head of North America, Peter Anastasiou, now reveals his new job title in a post on social media LinkedIn.

From January, he will join US-based biotech firm Capsida Biotherapeutics as its CEO, he announces in the statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs